Pharmaceutical
Upcoming Earnings
Biotechnology

Alexion Pharmaceuticals

$123.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (0.08%) Today
+$1.08 (0.88%) As of 7:54 PM EDT after-hours

Why Robinhood?

You can buy or sell ALXN and other stocks, options, ETFs, and crypto commission-free!

About ALXN

Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Read More Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Employees
2,656
Headquarters
Boston, Massachusetts
Founded
1992
Market Cap
27.42B
Price-Earnings Ratio
67.06
Dividend Yield
0.00
Average Volume
1.46M
High Today
$123.07
Low Today
$121.52
Open Price
$122.42
Volume
1.54M
52 Week High
$141.86
52 Week Low
$92.56

Collections

Pharmaceutical
Upcoming Earnings
Biotechnology
Biopharmaceutical
Health
Therapy
Technology
US

ALXN News

CNBCJul 5

Stocks making the biggest moves premarket: Qualcomm, Rio Tinto, Alexion Pharmaceuticals & more

226
BenzingaJun 27

Alexion Confirms FDA Approval For Soliris

431
BenzingaJun 27

Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder who are Anti-Aquaporin-4 Antibody Positive

98

ALXN Earnings

$1.28
$1.65
$2.02
$2.39
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
$2.33 per share
Actual
Available Jul 24, Pre-Market

Popular Stocks

More ALXN News

Yahoo FinanceJun 21

Alexion's sBLA for Ultomiris Gets Priority Review From FDA

100
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.